Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 100% Improvement Relative Risk Ventilator free days 48% primary Ventilation time 38% ICU free days 43% ICU time 38% GI complications while ve.. 78% Ivermectin  Shimizu et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 88 patients in Japan (December 2020 - May 2021) Lower mortality (p=0.001) and ventilation (p=0.027) Shimizu et al., J. Infection and Chemo.., Dec 2021 Favors ivermectin Favors control

Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis

Shimizu et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024
Dec 2021  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 88 ventilated COVID-19 patients in Japan, 39 treated with ivermectin within 3 days of admission, showing significantly reduced incidence of GI complications and mortality, and increased ventilator-free days with treatment.
This is the 74th of 100 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion). 47 studies are RCTs, which show efficacy with p=0.0000002.
risk of death, 99.9% lower, HR 0.001, p < 0.001, treatment 0 of 39 (0.0%), control 8 of 49 (16.3%), NNT 6.1, adjusted per study, Cox proportional hazard regression.
ventilator free days, 47.9% lower, OR 0.52, p = 0.03, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, primary outcome, RR approximated with OR.
ventilation time, 38.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.
ICU free days, 42.8% lower, OR 0.57, p = 0.06, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, RR approximated with OR.
ICU time, 37.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.
GI complications while ventilated, 77.9% lower, RR 0.22, p = 0.03, treatment 39, control 49, adjusted per study, Cox proportional hazard regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shimizu et al., 31 Dec 2021, retrospective, Japan, peer-reviewed, 11 authors, study period December 2020 - May 2021, dosage 200μg/kg days 1, 14.
This PaperIvermectinAll
Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis
M.D. Kentaro Shimizu, Haruhiko Hirata, Daijiro Kabata, Natsuko Tokuhira, Moe Koide, Akiko Ueda, Jotaro Tachino, Ayumi Shintani, Akinori Uchiyama, Yuji Fujino, Hiroshi Ogura
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conclusions The administration of ivermectin improved GI complications and VFD in ventilated patients with COVID-19. The beneficial influence of ivermectin on the intestines may improve outcome in these patients. Further research is needed to investigate the mechanism and effects of ivermectin treatment. Conflict of interest The authors declare that they have no conflict of interests.
Beigel, What is the role of remdesivir in patients with covid-19?, Curr Opin Crit Care, doi:10.1097/MCC.0000000000000866
Bone, Balk, Cerra, Dellinger, Fein et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The accp/sccm consensus conference committee. American college of chest physicians/society of critical care medicine, Chest
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of sars-cov-2 in vitro, Antiviral Res
Clark, Coopersmith, Intestinal crosstalk: A new paradigm for understanding the gut as the "motor" of critical illness, Shock
D'amico, Baumgart, Danese, Peyrin-Biroulet, Diarrhea during covid-19 infection: Pathogenesis, epidemiology, prevention, and management, Clin Gastroenterol Hepatol
Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with covid-19, N Engl J Med
Hashimoto, Perlot, Rehman, Trichereau, Ishiguro et al., Ace2 links amino acid malnutrition to microbial ecology and intestinal inflammation, Nature
Lopez-Medina, Lopez, Hurtado, Davalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild covid-19: A randomized clinical trial, JAMA
Lv, Gu, Jiang, Yan, Chen et al., Gut mycobiota alterations in patients with covid-19 and h1n1 infections and their associations with clinical features, Commun Biol
Mao, Qiu, He, Tan, Li et al., Manifestations and prognosis of gastrointestinal and liver involvement in patients with covid-19: A systematic review and meta-analysis, Lancet Gastroenterol Hepatol
Mikasa, Aoki, Aoki, Abe, Iwata et al., JAID/JSC guidelines for the treatment of respiratory infectious diseases: The japanese association for infectious diseases/japanese society of chemotherapy -the JAID/JSC guide to clinical management of infectious disease/guideline-preparing committee respiratory infectious disease wg. J Infect J o u r n a l P r e -p r o, o f Chemother
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in covid nineteen study, Chest
Salem, A response to the recommendations for using dexamethasone for the treatment of covid-19: The dark side of dexamethasone, J Pharm Pract
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of covid-19, Clin Pharmacol Ther
Schoenfeld, Bernard, Network, Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome, Crit Care Med
Shimizu, Hibino, Biros, Irisawa, Shimazu, Emergency medicine in japan: Past, present, and future, International Journal of Emergency Medicine
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe covid-19: A J o u r n a l P r e -p r o o f randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Wehbe, Wehbe, Iratni, Pintus, Zaraket et al., Repurposing ivermectin for covid-19: Molecular aspects and therapeutic possibilities, Front Immunol
White, Dhillon, Hughes, Faggian, Soni, A national strategy to diagnose covid-19 associated invasive fungal disease in the icu, Clin Infect Dis, doi:10.1093/cid/ciaa1298
Wu, Cheng, Jiang, Tang, Tang, Altered oral and gut microbiota and its association with sars-cov-2 viral load in covid-19 patients during hospitalization, NPJ Biofilms Microbiomes
Xiao, Tang, Zheng, Liu, Li et al., Evidence for gastrointestinal infection of sars-cov-2, Gastroenterology
Yagisawa, Foster, Hanaki, Omura, Global trends in clinical studies of ivermectin in covid-19, Jpn J Antibiot
Zein, Sulistiyana, Raffaelo, Pranata, Ivermectin and mortality in patients with covid-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes Metab Syndr
Zuo, Zhang, Lui, Yeoh, Li et al., Alterations in gut microbiota of patients with covid-19 during time of hospitalization, Gastroenterology
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop